NIH researchers highlight progress, path forward for developing TB vaccines
Since that time, TB researchers have assembled a significant pipeline of vaccine candidates and assessed them in clinical trials. However, to transform the field and help make licensure of new vaccines a reality, the editorial co-authors stress, scientists must investigate remaining fundamental questions, including the following:
Why does infection with the TB bacterium cause active disease in some people but not others? Why does the current licensed TB vaccine, Bacille Calmette-Guérin, protect children more effectively than adults? What immune responses must effective vaccines elicit to successfully protect against TB? NIAID, part of the team that helped to develop both iterations of the Blueprint, supports scientists working worldwide to contribute important data to these and other areas of inquiry. The authors also note that along with basic and clinical trial data, recent innovations in systems biology, genomics and bioinformatics, animal modeling, and immunologic and molecular tools will play important roles in developing safe and effective TB vaccines. The authors emphasize that close coordination among biomedical researchers, product developers, funders and TB health care programs worldwide will be essential to eventually develop and deliver new vaccines as part of the global fight against TB.
INFORMATION:
ARTICLE:
C Sizemore and AS Fauci. Transforming biomedical research to develop effective TB vaccines: The next ten years. Tuberculosis 92(S1):S2-S3 (2012).
WHO:
NIAID Director Anthony S. Fauci, M.D., and Christine Sizemore, Ph.D., chief of the Tuberculosis, Leprosy and Other Mycobacterial Diseases Section in NIAID's Division of Microbiology and Infectious Diseases, are available to discuss their editorial.
CONTACT:
To schedule interviews, please contact Nalini Padmanabhan, (301) 402-1663, padmanabhannm@niaid.nih.gov.
For more information about the original Blueprint published in 2000, see the NIAID news release announcing its publication. For more information about NIAID's TB research, visit the NIAID Tuberculosis Web portal. NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.
Why does infection with the TB bacterium cause active disease in some people but not others? Why does the current licensed TB vaccine, Bacille Calmette-Guérin, protect children more effectively than adults? What immune responses must effective vaccines elicit to successfully protect against TB? NIAID, part of the team that helped to develop both iterations of the Blueprint, supports scientists working worldwide to contribute important data to these and other areas of inquiry. The authors also note that along with basic and clinical trial data, recent innovations in systems biology, genomics and bioinformatics, animal modeling, and immunologic and molecular tools will play important roles in developing safe and effective TB vaccines. The authors emphasize that close coordination among biomedical researchers, product developers, funders and TB health care programs worldwide will be essential to eventually develop and deliver new vaccines as part of the global fight against TB.
INFORMATION:
ARTICLE:
C Sizemore and AS Fauci. Transforming biomedical research to develop effective TB vaccines: The next ten years. Tuberculosis 92(S1):S2-S3 (2012).
WHO:
NIAID Director Anthony S. Fauci, M.D., and Christine Sizemore, Ph.D., chief of the Tuberculosis, Leprosy and Other Mycobacterial Diseases Section in NIAID's Division of Microbiology and Infectious Diseases, are available to discuss their editorial.
CONTACT:
To schedule interviews, please contact Nalini Padmanabhan, (301) 402-1663, padmanabhannm@niaid.nih.gov.
For more information about the original Blueprint published in 2000, see the NIAID news release announcing its publication. For more information about NIAID's TB research, visit the NIAID Tuberculosis Web portal. NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.
END